Skip to main content

Table 1 Electrocardiogram characteristics of patients according to incidence of new-onset AF during follow-up

From: Interatrial block, P terminal force or fragmented QRS do not predict new-onset atrial fibrillation in patients with severe chronic kidney disease

  No AF
(N = 136)
Incident AF
(N = 29)
p
ECG
PR-intervala
  mean (median) ms 176 (168) 180 (168) 0.48
P-wave durationa
  mean (median) ms 117 (120) 118 (120) 0.79
Biphasic P-waves (> 1)b 5 (3.7) 2 (6.9) 0.61
  Terminal P negativity depth
  mean (median) mVc 0.5 (0.5) 0.6 (0.5) 0.39
Terminal P negativity duration
  mean (median) mmc 56 (50) 53 (60) 0.65
IABd 75 (55.1) 17 (58.6) 0.84
PTF > 0.04 mm*se 33 (24.3) 11 (37.9) 0.17
LAEf 113 (83.1) 24 (82.8) 1.0
QRS duration mean (median) ms 98 (95) 97 (96) 0.94
QTc duration mean (median) ms 442 (439) 426 (449) 0.44
QRS axis mean (median) degrees 25 (25) 15 (15) 0.15
fQRSg 121 (89.0) 23 (79.3) 0.22
fQRS positive leads mean (median) 5 (5) 4 (4) 0.07
fQRS positive in anterior leads aloneh 5 (3.7) 2 (6.9) 0.61
fQRS positive in lateral leads alonei 9 (6.6) 0 (0) 0.36
fQRS positive in inferior leads alonej 31 (22.8) 8 (27.6) 0.63
fQRS positive in ant + lat leads 3 (2.2) 0 (0) 1.0
fQRS positive in ant + inf leads 20 (14.7) 5 (17.2) 0.78
fQRS positive in lat + inf leads 33 (24.3) 8 (27.6) 0.81
fQRS positive in ant + lat + inf leads 20 (14.7) 0 (0) 0.03
Echocardiography
LA diameter mean (median) mm* 40 (39) 44 (42) 0.01
EF mean (median) % 65 (65) 65 (66) 0.22
Laboratory tests
NT-ProBNP median (IQR) ng/l 808 (1632) 1390 (5064) 0.10
Clinical charateristics
CHA2DS2-VASc-score median (IQR) 2 (2) 3 (3) 0.03
  1. *data is missing in 28 (17.0%) cases
  2. ameasured in lead II; b measured in leads II, III and aVF; c measured in lead V1; d defined according to ECG-criteria (total P-wave duration ≥120 ms in lead II ± more than one biphasic P-waves in leads II, III or aVF); e defined according to ECG-criteria (the product of the duration (in seconds) and depth (in millimeters) of the terminal negative portion of P-wave in lead V1); f defined according to ECG-criteria (total P-wave duration ≥120 ms in lead II ± more than one biphasic P-waves in leads II, III or aVF; or duration of terminal negative portion of P-wave in lead V1 > 40 ms or depth of terminal negative portion of P-wave in lead V1 > 1 mm); g defined according to ECG-criteria (presence of a notched R or S wave or the presence of one or more additional R waves (R’) or, in the presence of a wide QRS complex (> 120 ms), more than two notches in R or S waves in two contiguous leads corresponding to a major coronary artery, respectively.); h measured in leads V1-V4; i measured in leads V5-V6 and I and aVL; j measured in leads II-III and aVF
  3. Values in parentheses are % unless stated otherwise. ECG = electrocardiogram; IAB = interatrial block; PTF = P terminal force; LAE = left atrial enlargement; fQRS = fragmented QRS; LA = left atrium; EF = ejection fraction; NT-ProBNP = N-terminal pro b-type natriuretic peptide; IQR = inter-quartile range; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years and sex category (female, unless < 65 years and no other risk factors)